[A24-126] Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
Last updated 01.04.2025
Project no.:
A24-126
Commission:
Commission awarded on 20.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) with locally advanced NSCLC for whom surgical resection or platinum-based chemoradiation is not an option, or with metastatic NSCLC
- Patients with PD‑L1‑expression ≥ 50% and without treatable genetic alterations: added benefit not proven
- Patients with PD‑L1‑expression < 50% and without treatable genetic alterations: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-126
| Project no. | Title | Status |
|---|---|---|
| A24-131 | Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-129 | Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-128 | Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
| A24-130 | Tislelizumab (oesophageal squamous cell carcinoma, second line) – Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
| A24-127 | Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |